

17.30 - 20.00

Clinical Cancer Genomics 2025

Whole genomes and transcriptomes: from clinic to research and back Social media handle: #CCG2025; www.ccg2025.eu

Thursday March 20th

Session 1: Current state of the art: Ov	verview of European national	I cancer whole genome	sequencing
initiatives and FU 1+MG			

9.00 - 9.10	Welcome by Edwin Cuppen on behalf of program committee plus brief intro about the venue by host organisation
9.10 - 9.20	Matthew Brown , Genomics England, UK WGS in a national cancer personalised medicine program; the Genomics England experience
9.20 - 9.30	Frédérique Nowak , 2025 France Genomic Medicine Initiative, France PFMG2025 - Integrating genomic medicine into the national healthcare system in France
9.30 - 9.40	Richard Rosenquist Brandell , Genomic Medicine Sweden, Sweden <i>Implementing WGTS</i> in a regionalised healthcare system
9.40 - 9.50	Bettina Lundgren, Danish National Genome Center, Denmark Five years with Danish National Genome Center
9.50 - 10.00	Stefan Fröhling , DKFZ/NCT, Germany DKFZ/NCT/DKTK MASTER: Whole-Genome and Transcriptome Sequencing for Precision Oncology in Germany
10.00 - 10.10	Edwin Cuppen , Hartwig Medical Foundation, Netherlands Routine whole genome sequencing-based cancer diagnostics for care and research in The Netherlands.
10.10 - 10.40	Panel discussion with previous speakers
10.40 - 11.10	Coffee/Tea Break (with exhibitors/sponsors and posters)
11.10 - 11.30	Giovanni Tonon , Università Vita-Salute San Raffaele, Alliance against Cancer, Milan, Italy <i>The 1+MG initiatives on cancer</i>
11.30 - 11.50	Ivo Gut, CNAG Barcelona, Spain title tbc
11.50 - 12.10	Eva Winkler, University of Heidelberg, Germany title tbc
12.10 - 12.30	Poster flash talks (1 slide, 1 minute)
12.30 - 13.00	Lunch Break (with exhibitors/sponsors)
13.00 - 14.00	Poster session (and continued lunch)

Session 2: The clinical perspective: implementation and impact		
14.00 - 14.25	David Tamborero , Karolinska Institute, Sweden Implementation of an academic clinical decision support system in the routine and in the investigational oncology setting	
14.25 - 14.50	Birgit Geoerger , Gustave Roussy, France Genomics in therapeutic proof-of-concept precision cancer medicine platform trials	
14.50 - 15.15	Emile Voest, NKI-AvL, Netherlands The science behind genomics is driving quality of cancer care	
15.15 - 16.00	Coffee/Tea Break (with exhibitors/sponsors and posters)	
16.00 - 16.25	Torsten Haferlach , MLL Munich Leukemia Laboratory, Germany WGS in leukemia diagnostics: to be or not to be?	
16.25 - 16.40	Abstract selected speaker title tbc	
16.40 - 17.30	Keynote Lecture: Charles Swanton, Francis Crick Institute, UK Myeloid Mayhem, tumour initiation and metastatic progression	

Reception (drinks & walking dinner, included in registration)



Clinical Cancer Genomics 2025

Whole genomes and transcriptomes: from clinic to research and back Social media handle: #CCG2025; www.ccg2025.eu

Friday March 21st

Session 3. The	research perspective: Big data analyses and impact on clinic
9.00 - 9.25	Stefan Pfister, KiTZ Heidelberg, Germany title tbc
9.25 - 9.50	Ruben van Boxtel, Princess Máxima Center, Utrecht, The Netherlands Tracking mutational footprints to study cancer causes
9.50 - 10.15	Kristoffer Staal Rhorberg, Righospitalet, Denmark Use of genomes and other biomarkers when selecting patients for research
10.15 - 10.30	Abstract selected speaker title tbc
10.30 - 11.00	Coffee/Tea Break (with exhibitors/sponsors and posters)
11.00 - 11.25	Alena Gros, Vall d'Hebron Institute of Oncology (VHIO), Spain Personalized antitumor T-cell therapies targeting neoantigens
11.25 - 11.50	Joris van de Haar, NKI-AvL, Netherlands title tbc
11.50 - 12.05	Abstract selected speaker title tbc
12.05 - 12.20	Abstract selected speaker title tbc
12.20 - 13.30	Lunch Break (with exhibitors/sponsors)
Session 4: The	future perspective: data-driven cancer care
13.30 - 13.55	David Gisselsson Nord , Genomic Medicine Sweden and Lund University, Sweden BrainChild: a national platform for integrating big data from childhood cancer patients
	Brain Child. a national platform for integrating big data from childhood cancer patients
13.55 - 14.20	Moritz Gerstung, German Cancer Research Center (DKFZ), Germany Using AI to Understand Cancer Development
13.55 - 14.20 14.20 - 14.45	Moritz Gerstung, German Cancer Research Center (DKFZ), Germany
	Moritz Gerstung, German Cancer Research Center (DKFZ), Germany Using Al to Understand Cancer Development Janne Lehtiö, Karolinska Institute, Sweden
14.20 - 14.45	Moritz Gerstung, German Cancer Research Center (DKFZ), Germany Using Al to Understand Cancer Development Janne Lehtiö, Karolinska Institute, Sweden title tbc Abstract selected speaker
14.20 - 14.45 14.45 - 15.00	Moritz Gerstung, German Cancer Research Center (DKFZ), Germany Using Al to Understand Cancer Development Janne Lehtiö, Karolinska Institute, Sweden title tbc Abstract selected speaker title tbc
14.20 - 14.45 14.45 - 15.00 15.00 - 15.45	Moritz Gerstung, German Cancer Research Center (DKFZ), Germany Using Al to Understand Cancer Development Janne Lehtiö, Karolinska Institute, Sweden title tbc Abstract selected speaker title tbc Coffee/Tea Break (with exhibitors/sponsors and posters) Abstract selected speaker
14.20 - 14.45 14.45 - 15.00 15.00 - 15.45 15.45 - 16.00	Moritz Gerstung, German Cancer Research Center (DKFZ), Germany Using Al to Understand Cancer Development Janne Lehtiö, Karolinska Institute, Sweden title tbc Abstract selected speaker title tbc Coffee/Tea Break (with exhibitors/sponsors and posters) Abstract selected speaker title tbc Abstract selected speaker
14.20 - 14.45 14.45 - 15.00 15.00 - 15.45 15.45 - 16.00 16.10 - 16.25	Moritz Gerstung, German Cancer Research Center (DKFZ), Germany Using AI to Understand Cancer Development Janne Lehtiö, Karolinska Institute, Sweden title tbc Abstract selected speaker title tbc Coffee/Tea Break (with exhibitors/sponsors and posters) Abstract selected speaker title tbc Abstract selected speaker title tbc Keynote Lecture: Nuria Bigas Lopez, ICREA and Institute for Research in Biomedicine Barcelona (IRB)